Anti-PD1/PDL1 induced psoriasis

Voudouri, Dimitra; Nikolaou, Vasiliki; Laschos, Konstantinos; Charpidou, Andriani; Soupos, Nikolaos; Triantafyllopoulou, Ioanna; Panoutsopoulou, Ioanna G.; Aravantinos, G.; Syrigos, Konstantinos; Stratigos, Alexander J.

doi:10.1016/j.currproblcancer.2017.10.003

Cited by 98 publications

(77 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is an uncommon disorder; a literature search results in mostly case reports, with some noting an association between pyoderma faciale and IBD. [1][2][3][4] This is the first reported case, to our knowledge, of pyoderma faciale occurring in the setting of SIBO.…”

Section: Follicular Psoriasis Induced By Pembrolizumab In a Patient Wmentioning

confidence: 72%

“…3 The mechanism of induction of psoriasis by pembrolizumab is still unclear, but it is probably due to the activation of Th17 lymphocytes, normally downregulated by PD1. 4 Follicular psoriasis (FP) is a rare entity that must be differentiated from other clinically similar diseases, especially keratosis pilaris. Dermatoscopy could be a great help in recognizing this condition.…”

Section: Follicular Psoriasis Induced By Pembrolizumab In a Patient Wmentioning

confidence: 99%

See 1 more Smart Citation

Follicular psoriasis induced by pembrolizumab in a patient with advanced non‐small‐cell lung cancer

et al. 2019

View full text Add to dashboard Cite

Section: Follicular Psoriasis Induced By Pembrolizumab In a Patient Wmentioning

confidence: 72%

Section: Follicular Psoriasis Induced By Pembrolizumab In a Patient Wmentioning

confidence: 99%

Follicular psoriasis induced by pembrolizumab in a patient with advanced non‐small‐cell lung cancer

et al. 2019

View full text Add to dashboard Cite

“…These treatment options are currently topical corticosteroids, vitamin D analogues, ultraviolet-based phototherapy, and systemic treatments, such as methotrexate, acitretin, and fumaric acid esters, and biologics [11]. Because of the underlying malignant condition, cyclosporine and many of the novel biologic agents are preferably avoided in patients with PD-1/PDL-1-induced psoriasis unless other severe irAEs are present, e.g., ICI-induced colitis not responding to systemic corticotherapy [3]. Our patient was successfully treated with topical steroids and prolongation of the dosing interval of nivolumab.…”

Section: Discussionmentioning

confidence: 99%

“…Twelve individual cases were described. Two authors published a collection of 17 and 5 cases, respectively, in 1 publication [2, 3]. Two additional publications also reported on psoriasis exacerbation but were not included in the tables because detailed information is missing [4, 5].…”

Section: Literature Reviewmentioning

confidence: 99%

Psoriasis Vulgaris Exacerbation during Treatment with a PD-1 Checkpoint Inhibitor: Case Report and Literature Review

et al. 2018

View full text Add to dashboard Cite

Objective: The incidence of immune-related adverse events is growing as the use of checkpoint inhibitors is exponentially increasing. Cutaneous adverse events are among the most frequent immune-related adverse events. The purpose of this case report and literature review is to highlight psoriasis as a potential adverse event with need for early recognition. Case Report and Literature Review: We describe the case of a 65-year-old woman with psoriasis exacerbation while treated with nivolumab (anti-PD-1) for a stage IV melanoma. She had a history of scalp psoriasis but she presented with psoriatic lesions on both lower and upper limbs. Our patient was treated with topical steroids. So far, 34 other cases with an exacerbation of psoriasis during treatment with anti-PDL-1 or PD-1 therapy have been reported in the literature. A broad range of therapies are described, without any available guidelines for this particular condition. Conclusion: Psoriasis exacerbation is an established side effect of PD-1/PDL-1 checkpoint inhibitors with 35 reported cases. Early recognition and management are challenging as there are no clear guidelines available. A close collaboration between oncologist and dermatologist is mandatory to manage this immune-related adverse event.

show abstract

“…Exacerbation or occurrence of psoriasis is observed in the course of treatment with ICIs . De novo psoriasis may occur after several months of treatment.…”

Section: Psoriasismentioning

confidence: 99%

Management of immune checkpoint inhibitor‐related dermatologic adverse events

Liu

et al. 2019

Thoracic Cancer

View full text Add to dashboard Cite

Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment. The unique spectrum of immune-related adverse events (IrAEs) may occur during treatment. Dermatologic toxicities appear to be one of the most prevalent immunotherapy-related adverse events. The most common symptoms are maculopapular rash and pruritus. Serious dermatologic toxicities including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reactions with eosinophilia and systemic symptoms are rare. In this review, we summarize guidelines of management of immunotherapy-related toxicities, case reports, and proposed treatment recommendation. Key pointsThis review will enable clinical oncologists to recognize, diagnose, and manage immune checkpoint inhibitor-related dermatologic adverse events.

show abstract

Anti-PD1/PDL1 induced psoriasis

Cited by 98 publications

References 9 publications

Follicular psoriasis induced by pembrolizumab in a patient with advanced non‐small‐cell lung cancer

Follicular psoriasis induced by pembrolizumab in a patient with advanced non‐small‐cell lung cancer

Psoriasis Vulgaris Exacerbation during Treatment with a PD-1 Checkpoint Inhibitor: Case Report and Literature Review

Management of immune checkpoint inhibitor‐related dermatologic adverse events

Contact Info

Product

Resources

About